Poxel SA
Research Poxel SA (POXEL) on Bullrun: market cap EUR 11.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPOXEL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 11.01M
- Financial periodFY2024
- RevenueEUR 6.64M
- Revenue growth235.0%
- Net income-EUR 18.31M
- Gross margin55.7%
Valuation Snapshot
latest market cap is EUR 11.01M.
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
Frequently asked questions
What is Poxel SA's market cap?
Poxel SA's market capitalization is EUR 11.01M.
What does Poxel SA do?
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction.